Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832

Watchlist Manager
Shenzhen New Industries Biomedical Engineering Co Ltd Logo
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Watchlist
Price: 59.87 CNY 0.1% Market Closed
Market Cap: 47B CNY

Shenzhen New Industries Biomedical Engineering Co Ltd
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Shenzhen New Industries Biomedical Engineering Co Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Cash & Cash Equivalents
ÂĄ919.5m
CAGR 3-Years
14%
CAGR 5-Years
-14%
CAGR 10-Years
14%
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
Cash & Cash Equivalents
ÂĄ8.9B
CAGR 3-Years
10%
CAGR 5-Years
13%
CAGR 10-Years
N/A
S
Shanghai Conant Optical Co Ltd
HKEX:2276
Cash & Cash Equivalents
ÂĄ335.6m
CAGR 3-Years
-17%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Autobio Diagnostics Co Ltd
SSE:603658
Cash & Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Winner Medical Co Ltd
SZSE:300888
Cash & Cash Equivalents
ÂĄ1.4B
CAGR 3-Years
-31%
CAGR 5-Years
24%
CAGR 10-Years
N/A
Intco Medical Technology Co Ltd
SZSE:300677
Cash & Cash Equivalents
ÂĄ4.3B
CAGR 3-Years
-12%
CAGR 5-Years
2%
CAGR 10-Years
N/A
No Stocks Found

Shenzhen New Industries Biomedical Engineering Co Ltd
Glance View

Market Cap
47B CNY
Industry
Health Care

Amidst the sprawling innovation-centric landscape of Shenzhen, Shenzhen New Industries Biomedical Engineering Co., Ltd., often abbreviated as SNIBE, stands out as a beacon in the realm of biotechnology. Founded in 1995, SNIBE has steadily carved out a significant niche in the medical devices industry, particularly in in-vitro diagnostic products. The company has become synonymous with the development, manufacture, and sale of diagnostic reagents and fully automated chemiluminescence immunoassay systems, which have gained widespread recognition in over 150 countries. By focusing on the integration of cutting-edge technology in diagnostic immunoassays, SNIBE ensures that hospitals and laboratories worldwide can attain high accuracy and efficiency in medical testing, while concurrently meeting the growing global demand for advanced diagnostic tools. The financial engine that propels SNIBE is powered by its robust supply chain and diversified product offerings. With its line-up of innovative diagnostic products, the company generates the bulk of its revenue through long-term contracts with health institutions, research centers, and clinical laboratories. These partnerships are augmented by continuous investment in research and development, ensuring a steady flow of novel products capable of addressing pressing medical needs. Additionally, SNIBE’s strategic emphasis on international markets has fortified its revenue streams, allowing it to mitigate risks associated with saturation or volatility in domestic markets. Through its unwavering focus on innovation and strategic expansion, SNIBE not only sustains its financial health but also continually contributes to advancements in global healthcare diagnostics.

Intrinsic Value
72.12 CNY
Undervaluation 17%
Intrinsic Value
Price

See Also

What is Shenzhen New Industries Biomedical Engineering Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
919.5m CNY

Based on the financial report for Dec 31, 2024, Shenzhen New Industries Biomedical Engineering Co Ltd's Cash & Cash Equivalents amounts to 919.5m CNY.

What is Shenzhen New Industries Biomedical Engineering Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
14%

Over the last year, the Cash & Cash Equivalents growth was -12%. The average annual Cash & Cash Equivalents growth rates for Shenzhen New Industries Biomedical Engineering Co Ltd have been 14% over the past three years , -14% over the past five years , and 14% over the past ten years .

Back to Top